TrialHuman vaccines & immunotherapeutics2023

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12-17 year-old adolescents.

Pio Lopez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.